Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polyphenon E for Cervical Cancer Prevention
NCT00303823Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2005
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cervical intraepithelial neoplasia (CIN) and human papillomavirus infection comparing Polyphenon E with Placebo (2 arms). Primary endpoints: Clearance of Oncogenic Human Papillomavirus (HPV) and Complete Colposcopic, Histologic and Cytologic Clearance of Disease at 4 months, Clearance of Oncogenic HPV With Evidence of Low Grade Cervical Intraepithelial Neoplasia at 4 months and 2 more. Started Sep 2005; status: completed.
02
Drugs
green tea extract
03
Conditions
cervical intraepithelial neoplasia (CIN)human papillomavirus infection
Beyond the preview
Go deeper on NCT00303823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00303823.